Bios Health Group has entered the life sciences market. This new company entity is a strategic partner providing solutions for life science companies and investors. It offers strategies to attract funding, optimize clinical development, and create effective commercial strategies. Bios Health Group also serves as a venture partner providing investor preparation for Bbotech companies seeking investment funding and access to venture funds through its investor networks.
Bios Health Group Chief Executive Officer, Zizi Uzezi Imatorbhebhe, MBA MS PMP® said in a press release, "We are thrilled to bring this comprehensive suite of end-to-end solutions to biotech and life science companies. Our strategic approach involves engagement with venture capitalists and investors, effectively addressing the funding gap that often impedes early-stage biotech companies from accessing critical financial resources required to realize their innovative concepts. Additionally, we provide established companies with proven commercial strategies to launch new products and expand their market presence."
Bios Health Group offers four strategic solutions:
Bios Health Group Enters the Market to Offer Investment-Driven and Clinical Development Optimization Strategies for Biotech and Life Science Companies. (2023, August 15). Cision PR Newswire.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.